ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike

Johnson & Johnson (JNJ) infused positive optimism for the broader healthcare sector after posting solid third-quarter 2024 earnings on Oct. 15. The world's biggest healthcare products maker continued with its long streak of earnings beat and also beat revenue estimates. Impressed with the earnings results, a few analysts raised their target price on the stock.Given this, investors should tap the company’s growth prospects through ETFs with the largest allocation to this diversified drug maker. These include ...